

# Ted Cohen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6267607/publications.pdf>

Version: 2024-02-01

200  
papers

10,903  
citations

41344

49  
h-index

40979

93  
g-index

221  
all docs

221  
docs citations

221  
times ranked

12679  
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021. <i>Clinical Infectious Diseases</i> , 2023, 76, e350-e359.	5.8	9
2	Trends, Mechanisms, and Racial/Ethnic Differences of Tuberculosis Incidence in the US-Born Population Aged 50 Years or Older in the United States. <i>Clinical Infectious Diseases</i> , 2022, 74, 1594-1603.	5.8	9
3	The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. <i>Epidemiology</i> , 2022, 33, 75-83.	2.7	2
4	vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding. <i>BMC Bioinformatics</i> , 2022, 23, 22.	2.6	2
5	Global estimates of paediatric tuberculosis incidence in 2013â€“19: a mathematical modelling analysis. <i>The Lancet Global Health</i> , 2022, 10, e207-e215.	6.3	23
6	Spatially targeted digital chest radiography to reduce tuberculosis in high-burden settings: A study of adaptive decision making. <i>Epidemics</i> , 2022, 38, 100540.	3.0	0
7	The role of prisons in disseminating tuberculosis in Brazil: A genomic epidemiology study. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100186.	2.6	10
8	Evaluating spatially adaptive guidelines for the treatment of gonorrhoea to reduce the incidence of gonococcal infection and increase the effective lifespan of antibiotics. <i>PLoS Computational Biology</i> , 2022, 18, e1009842.	3.2	1
9	Phylogeography and transmission of <i>M. tuberculosis</i> in Moldova: A prospective genomic analysis. <i>PLoS Medicine</i> , 2022, 19, e1003933.	8.4	16
10	A Cluster-based Method to Quantify Individual Heterogeneity in Tuberculosis Transmission. <i>Epidemiology</i> , 2022, 33, 217-227.	2.7	5
11	Neighbourhood prevalence-to-notification ratios for adult bacteriologically-confirmed tuberculosis reveals hotspots of underdiagnosis in Blantyre, Malawi. <i>PLoS ONE</i> , 2022, 17, e0268749.	2.5	6
12	Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods. , 2022, 1, e0000059.		1
13	Yield, Efficiency, and Costs of Mass Screening Algorithms for Tuberculosis in Brazilian Prisons. <i>Clinical Infectious Diseases</i> , 2021, 72, 771-777.	5.8	27
14	Ongoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children <i>versus</i> adults. <i>European Respiratory Journal</i> , 2021, 57, 2002504.	6.7	4
15	Development of a Treatment-decision Algorithm for Human Immunodeficiency Virusâ€“uninfected Children Evaluated for Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2021, 73, e904-e912.	5.8	19
16	Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic. <i>Medical Decision Making</i> , 2021, 41, 386-392.	2.4	7
17	Protective impacts of household-based tuberculosis contact tracing are robust across endemic incidence levels and community contact patterns. <i>PLoS Computational Biology</i> , 2021, 17, e1008713.	3.2	5
18	The Impact of Changes in Diagnostic Testing Practices on Estimates of COVID-19 Transmission in the United States. <i>American Journal of Epidemiology</i> , 2021, 190, 1908-1917.	3.4	49

#	ARTICLE	IF	CITATIONS
19	The escalating tuberculosis crisis in central and South American prisons. <i>Lancet, The</i> , 2021, 397, 1591-1596.	13.7	38
20	The positive externalities of migrant-based TB control strategy in a Chinese urban population with internal migration: a transmission-dynamic modeling study. <i>BMC Medicine</i> , 2021, 19, 95.	5.5	4
21	Incidence and prevalence of tuberculosis in incarcerated populations: a systematic review and meta-analysis. <i>Lancet Public Health, The</i> , 2021, 6, e300-e308.	10.0	54
22	Effectiveness of spatially targeted interventions for control of HIV, tuberculosis, leprosy and malaria: a systematic review. <i>BMJ Open</i> , 2021, 11, e044715.	1.9	13
23	Evolution and emergence of multidrug-resistant <i>Mycobacterium tuberculosis</i> in Chisinau, Moldova. <i>Microbial Genomics</i> , 2021, 7, .	2.0	5
24	Time Since Infection and Risks of Future Disease for Individuals with <i>Mycobacterium tuberculosis</i> Infection in the United States. <i>Epidemiology</i> , 2021, 32, 70-78.	2.7	16
25	Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. <i>The Lancet Global Health</i> , 2021, 9, e1679-e1687.	6.3	74
26	Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 356-365.	5.6	13
27	Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. <i>Addiction</i> , 2020, 115, 437-450.	3.3	15
28	Transmission Modeling with Regression Adjustment for Analyzing Household-based Studies of Infectious Disease. <i>Epidemiology</i> , 2020, 31, 238-247.	2.7	1
29	High-resolution estimates of tuberculosis incidence among non-U.S.-born persons residing in the United States, 2000-2016. <i>Epidemics</i> , 2020, 33, 100419.	3.0	6
30	Children as sentinels of tuberculosis transmission: disease mapping of programmatic data. <i>BMC Medicine</i> , 2020, 18, 234.	5.5	1
31	Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones. <i>PLoS Computational Biology</i> , 2020, 16, e1008106.	3.2	11
32	Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. <i>The Lancet Global Health</i> , 2020, 8, e1223-e1233.	6.3	15
33	Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. <i>BMC Infectious Diseases</i> , 2020, 20, 789.	2.9	10
34	The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. <i>Lancet, The</i> , 2020, 395, 973-984.	13.7	160
35	Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1567-1575.	5.6	14
36	Post-tuberculosis mortality and morbidity: valuing the hidden epidemic. <i>Lancet Respiratory Medicine, the</i> , 2020, 8, 332-333.	10.7	50

#	ARTICLE	IF	CITATIONS
37	Adaptive guidelines for the treatment of gonorrhea to increase the effective life span of antibiotics among men who have sex with men in the United States: A mathematical modeling study. PLoS Medicine, 2020, 17, e1003077.	8.4	6
38	Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 643-650.	2.1	4
39	Genomic variant-identification methods may alter Mycobacterium tuberculosis transmission inferences. Microbial Genomics, 2020, 6, .	2.0	24
40	Tracking and predicting U.S. influenza activity with a real-time surveillance network. PLoS Computational Biology, 2020, 16, e1008180.	3.2	8
41	Title is missing!. , 2020, 17, e1003077.		0
42	Title is missing!. , 2020, 17, e1003077.		0
43	Title is missing!. , 2020, 17, e1003077.		0
44	Title is missing!. , 2020, 17, e1003077.		0
45	Towards better prediction of Mycobacterium tuberculosis lineages from MIRU-VNTR data. Infection, Genetics and Evolution, 2019, 72, 59-66.	2.3	9
46	Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study. Medical Decision Making, 2019, 39, 553-567.	2.4	4
47	Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ: British Medical Journal, 2019, 367, l5894.	2.3	38
48	Beyond the SNP Threshold: Identifying Outbreak Clusters Using Inferred Transmissions. Molecular Biology and Evolution, 2019, 36, 587-603.	8.9	121
49	Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil. PLoS Medicine, 2019, 16, e1002737.	8.4	55
50	Disparities in access to diagnosis and care in Blantyre, Malawi, identified through enhanced tuberculosis surveillance and spatial analysis. BMC Medicine, 2019, 17, 21.	5.5	34
51	Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings. Lancet Infectious Diseases, The, 2019, 19, e89-e95.	9.1	41
52	Accurate quantification of uncertainty in epidemic parameter estimates and predictions using stochastic compartmental models. Statistical Methods in Medical Research, 2019, 28, 3591-3608.	1.5	9
53	Internal migration and transmission dynamics of tuberculosis in Shanghai, China: an epidemiological, spatial, genomic analysis. Lancet Infectious Diseases, The, 2018, 18, 788-795.	9.1	85
54	Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infectious Diseases, The, 2018, 18, e228-e238.	9.1	79

#	ARTICLE	IF	CITATIONS
55	Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. <i>The Lancet Global Health</i> , 2018, 6, e426-e435.	6.3	34
56	Risk ratios for contagious outcomes. <i>Journal of the Royal Society Interface</i> , 2018, 15, 20170696.	3.4	16
57	Pan-tuberculosis regimens: an argument for. <i>Lancet Respiratory Medicine</i> , 2018, 6, 239-240.	10.7	16
58	Protective effects of household-based TB interventions are robust to neighbourhood-level variation in exposure risk in Lima, Peru: a model-based analysis. <i>International Journal of Epidemiology</i> , 2018, 47, 185-192.	1.9	8
59	Evaluation of Tuberculosis Treatment Response With Serial C-Reactive Protein Measurements. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy253.	0.9	19
60	Use of daily Internet search query data improves real-time projections of influenza epidemics. <i>Journal of the Royal Society Interface</i> , 2018, 15, 20180220.	3.4	11
61	Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model. <i>American Journal of Epidemiology</i> , 2018, 187, 2011-2020.	3.4	58
62	Investigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and molecular epidemiological analysis. <i>BMC Medicine</i> , 2018, 16, 122.	5.5	39
63	Evidence sources on the natural history of latent tuberculosis infection. <i>Lancet Infectious Diseases</i> , 2018, 18, 834-835.	9.1	2
64	Where is tuberculosis transmission happening? Insights from the literature, new tools to study transmission and implications for the elimination of tuberculosis. <i>Respirology</i> , 2018, 23, 807-817.	2.3	17
65	Eliminating tuberculosis in low-burden countries. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 3-3.	1.2	5
66	The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study. <i>PLoS Medicine</i> , 2018, 15, e1002495.	8.4	12
67	Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 1336-1341.	1.4	15
68	Genomic analysis of globally diverse <i>Mycobacterium tuberculosis</i> strains provides insights into the emergence and spread of multidrug resistance. <i>Nature Genetics</i> , 2017, 49, 395-402.	21.4	258
69	Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?. <i>Lancet Infectious Diseases</i> , 2017, 17, e429-e433.	9.1	9
70	Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	1
71	Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. <i>International Journal of Infectious Diseases</i> , 2017, 56, 185-189.	3.3	14
72	A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	17

#	ARTICLE	IF	CITATIONS
73	Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. <i>The Lancet Global Health</i> , 2017, 5, e1123-e1132.	6.3	41
74	Drivers of Tuberculosis Transmission. <i>Journal of Infectious Diseases</i> , 2017, 216, S644-S653.	4.0	123
75	A Likelihood Approach for Real-Time Calibration of Stochastic Compartmental Epidemic Models. <i>PLoS Computational Biology</i> , 2017, 13, e1005257.	3.2	13
76	Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies. <i>PLoS Computational Biology</i> , 2017, 13, e1005321.	3.2	16
77	Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru. <i>Emerging Infectious Diseases</i> , 2017, 23, 1887-1890.	4.3	11
78	Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. <i>PLoS Medicine</i> , 2017, 14, e1002202.	8.4	20
79	The contributions of Steve Lawn to the science, advocacy and policy of HIV-associated TB. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1563-1564.	1.2	0
80	Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002142.	8.4	9
81	ClassTR: Classifying Within-Host Heterogeneity Based on Tandem Repeats with Application to <i>Mycobacterium tuberculosis</i> Infections. <i>PLoS Computational Biology</i> , 2016, 12, e1004475.	3.2	14
82	High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions. <i>European Respiratory Journal</i> , 2016, 48, 1227-1230.	6.7	33
83	Assessing the utility of Xpert <sup>®</sup> MTB/RIF as a screening tool for patients admitted to medical wards in South Africa. <i>Scientific Reports</i> , 2016, 6, 19391.	3.3	19
84	Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. <i>Aids</i> , 2016, 30, 2715-2723.	2.2	13
85	Rapid Drug Susceptibility Testing of Drug-Resistant <i>Mycobacterium tuberculosis</i> Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2058-2067.	3.9	76
86	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. <i>European Respiratory Journal</i> , 2016, 48, 1160-1170.	6.7	27
87	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. <i>The Lancet Global Health</i> , 2016, 4, e806-e815.	6.3	138
88	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. <i>The Lancet Global Health</i> , 2016, 4, e816-e826.	6.3	69
89	Reply to Chen et al. <i>Journal of Infectious Diseases</i> , 2016, 214, 1287-1288.	4.0	0
90	Identifying cost-effective dynamic policies to control epidemics. <i>Statistics in Medicine</i> , 2016, 35, 5189-5209.	1.6	12

#	ARTICLE	IF	CITATIONS
91	Genomic diversity in autopsy samples reveals within-host dissemination of HIV-associated <i>Mycobacterium tuberculosis</i> . <i>Nature Medicine</i> , 2016, 22, 1470-1474.	30.7	133
92	Spatial measurement errors in the field of spatial epidemiology. <i>International Journal of Health Geographics</i> , 2016, 15, 21.	2.5	26
93	Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2016, 16, 282.	2.9	57
94	The transmission of <i>Mycobacterium tuberculosis</i> in high burden settings. <i>Lancet Infectious Diseases</i> , 2016, 16, 227-238.	9.1	149
95	Whole-genome sequencing of <i>Mycobacterium tuberculosis</i> for rapid diagnostics and beyond. <i>Lancet Respiratory Medicine</i> , 2016, 4, 6-8.	10.7	13
96	Within-Host Heterogeneity of <i>Mycobacterium tuberculosis</i> Infection Is Associated With Poor Early Treatment Response: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2016, 213, 1796-1799.	4.0	45
97	Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant <i>Mycobacterium tuberculosis</i> : A Household-Based Case-Control Study. <i>Journal of Infectious Diseases</i> , 2016, 213, 149-155.	4.0	25
98	Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data. <i>Journal of Infectious Diseases</i> , 2016, 213, 287-294.	4.0	62
99	Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling. <i>PLoS ONE</i> , 2016, 11, e0153143.	2.5	2
100	Use of Lot Quality Assurance Sampling to Ascertain Levels of Drug Resistant Tuberculosis in Western Kenya. <i>PLoS ONE</i> , 2016, 11, e0154142.	2.5	6
101	HIV burden in men who have sex with men: a prospective cohort study 2007-2012. <i>Scientific Reports</i> , 2015, 5, 11205.	3.3	30
102	How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140306.	4.0	19
103	Evaluating the potential impact of enhancing HIV treatment and tuberculosis control programmes on the burden of tuberculosis. <i>Journal of the Royal Society Interface</i> , 2015, 12, 20150146.	3.4	9
104	Magnitude and sources of bias in the detection of mixed strain <i>M. tuberculosis</i> infection. <i>Journal of Theoretical Biology</i> , 2015, 368, 67-73.	1.7	19
105	Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens. <i>Microbiology and Molecular Biology Reviews</i> , 2015, 79, 101-116.	6.6	183
106	The potential impact of coinfection on antimicrobial chemotherapy and drug resistance. <i>Trends in Microbiology</i> , 2015, 23, 537-544.	7.7	36
107	Classic reaction kinetics can explain complex patterns of antibiotic action. <i>Science Translational Medicine</i> , 2015, 7, 287ra73.	12.4	67
108	The Distribution of Fitness Costs of Resistance-Confering Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis. <i>Clinical Infectious Diseases</i> , 2015, 61, S147-S154.	5.8	40

#	ARTICLE	IF	CITATIONS
109	Data for action: collection and use of local data to end tuberculosis. <i>Lancet, The</i> , 2015, 386, 2324-2333.	13.7	89
110	Effect of study design and setting on tuberculosis clustering estimates using Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeats (MIRU-VNTR): a systematic review. <i>BMJ Open</i> , 2015, 5, e005636-e005636.	1.9	20
111	Effect of empirical treatment on outcomes of clinical trials of diagnostic assays for tuberculosis. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 16-17.	9.1	12
112	How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance. <i>ELife</i> , 2015, 4, .	6.0	39
113	Changing Patterns of Spatial Clustering of Schistosomiasis in Southwest China between 1999â€“2001 and 2007â€“2008: Assessing Progress toward Eradication after the World Bank Loan Project. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 701-712.	2.6	11
114	Prospective evaluation of a complex public health intervention: lessons from an initial and follow-up cross-sectional survey of the tuberculosis strain typing service in England. <i>BMC Public Health</i> , 2014, 14, 1023.	2.9	18
115	The path of least resistance: aggressive or moderate treatment?. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2014, 281, 20140566.	2.6	79
116	High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. <i>European Respiratory Journal</i> , 2014, 43, 1132-1141.	6.7	26
117	Cigarette smoking among tuberculosis patients increases risk of transmission to child contacts. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1285-1291.	1.2	24
118	Bacillus Calmette-GuÃ©rin and Isoniazid Preventive Therapy Protect Contacts of Patients with Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 853-859.	5.6	30
119	Age-Specific Risks of Tuberculosis Infection From Household and Community Exposures and Opportunities for Interventions in a High-Burden Setting. <i>American Journal of Epidemiology</i> , 2014, 180, 853-861.	3.4	39
120	A tale of two settings: the role of the Beijing genotype in the epidemiology of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2014, 43, 632-635.	6.7	4
121	Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. <i>The Lancet Global Health</i> , 2014, 2, e581-e591.	6.3	55
122	Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. <i>Lancet, The</i> , 2014, 383, 1572-1579.	13.7	256
123	The Effect of HIV-Related Immunosuppression on the Risk of Tuberculosis Transmission to Household Contacts. <i>Clinical Infectious Diseases</i> , 2014, 58, 765-774.	5.8	51
124	The burden of tuberculosis disease in childrenâ€“Authors' reply. <i>Lancet, The</i> , 2014, 384, 1343-1344.	13.7	5
125	Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu073.	0.9	15
126	On the spread and control of MDR-TB epidemics: An examination of trends in anti-tuberculosis drug resistance surveillance data. <i>Drug Resistance Updates</i> , 2014, 17, 105-123.	14.4	33



#	ARTICLE	IF	CITATIONS
127	Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 341-352.	9.1	145
128	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. <i>The Lancet Global Health</i> , 2014, 2, e23-e34.	6.3	188
129	The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa. <i>Aids</i> , 2014, 28, S25-S34.	2.2	33
130	How can mathematical models advance tuberculosis control in high HIV prevalence settings?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 509-514.	1.2	25
131	High Rates of Potentially Infectious Tuberculosis and Multidrug-Resistant Tuberculosis (MDR-TB) among Hospital Inpatients in KwaZulu Natal, South Africa Indicate Risk of Nosocomial Transmission. <i>PLoS ONE</i> , 2014, 9, e90868.	2.5	34
132	Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations. <i>PLoS ONE</i> , 2014, 9, e110558.	2.5	23
133	The Impact of Antiretroviral Therapy on Mortality in HIV Positive People during Tuberculosis Treatment: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e112017.	2.5	63
134	Identifying dynamic tuberculosis case-finding policies for HIV/TB coepidemics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9457-9462.	7.1	34
135	Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country. <i>European Respiratory Journal</i> , 2013, 42, 1291-1301.	6.7	64
136	Evaluation of the Tuberculosis Strain Typing Service (TB-STs) in England. <i>Lancet</i> , The, 2013, 382, S73.	18.7	3
137	<i>Mycobacterium tuberculosis</i> mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. <i>Nature Genetics</i> , 2013, 45, 784-790.	21.4	405
138	Data needs for evidence-based decisions: a tuberculosis modeler's "wish list"™ [Review article]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 866-877.	1.2	57
139	How the Dynamics and Structure of Sexual Contact Networks Shape Pathogen Phylogenies. <i>PLoS Computational Biology</i> , 2013, 9, e1003105.	3.2	43
140	Bayesian Estimation of Mixture Models with Prespecified Elements to Compare Drug Resistance in Treatment-Naïve and Experienced Tuberculosis Cases. <i>PLoS Computational Biology</i> , 2013, 9, e1002973.	3.2	7
141	Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis. <i>Science Translational Medicine</i> , 2013, 5, 180ra49.	12.4	42
142	Response to Comment on "Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis". <i>Science Translational Medicine</i> , 2013, 5, 204lr4.	12.4	2
143	Planning for the invisible: projecting resources needed to identify and treat all patients with MDR-TB [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 427-428.	1.2	5
144	Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 373-380.	1.2	19

#	ARTICLE	IF	CITATIONS
145	Isoniazid-resistant Tuberculosis in Children. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e217-e226.	2.0	34
146	The impact of new tuberculosis diagnostics on transmission: why context matters. <i>Bulletin of the World Health Organization</i> , 2012, 90, 739-747.	3.3	51
147	Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. <i>PLoS Medicine</i> , 2012, 9, e1001347.	8.4	168
148	Multidrug Resistance Among New Tuberculosis Cases. <i>Epidemiology</i> , 2012, 23, 293-300.	2.7	13
149	Mixed-Strain Mycobacterium tuberculosis Infections and the Implications for Tuberculosis Treatment and Control. <i>Clinical Microbiology Reviews</i> , 2012, 25, 708-719.	13.6	172
150	Linking Surveillance with Action against Drug-Resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 399-401.	5.6	10
151	Controversies and Unresolved Issues in Tuberculosis Prevention and Control: A Low-Burden-Country Perspective. <i>Journal of Infectious Diseases</i> , 2012, 205, S293-S300.	4.0	26
152	Negative Control Exposures in Epidemiologic Studies. <i>Epidemiology</i> , 2012, 23, 351-352.	2.7	18
153	Modeling the Dynamic Relationship Between HIV and the Risk of Drug-Resistant Tuberculosis. <i>Science Translational Medicine</i> , 2012, 4, 135ra67.	12.4	30
154	Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007â€“2009. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 812-816.	1.2	42
155	Use of Spatial Information to Predict Multidrug Resistance in Tuberculosis Patients, Peru. <i>Emerging Infectious Diseases</i> , 2012, 18, 811-813.	4.3	13
156	The dynamics of sexual contact networks: Effects on disease spread and control. <i>Theoretical Population Biology</i> , 2012, 81, 89-96.	1.1	29
157	Identifying multidrug resistant tuberculosis transmission hotspots using routinely collected data. <i>Tuberculosis</i> , 2012, 92, 273-279.	1.9	20
158	Re: Supporting health systems for tuberculosis through research. <i>Tuberculosis</i> , 2012, 92, 290.	1.9	0
159	A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools [State of the art series. Operational research. Number 8 in the series]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 996-1004.	1.2	36
160	Test and treat in HIV: success could depend on rapid detection. <i>Lancet</i> , The, 2011, 378, 204-206.	13.7	14
161	Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy. <i>PLoS ONE</i> , 2011, 6, e18327.	2.5	71
162	Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994â€“2009. <i>PLoS ONE</i> , 2011, 6, e22927.	2.5	78

#	ARTICLE	IF	CITATIONS
163	Generalized Markov models of infectious disease spread: A novel framework for developing dynamic health policies. <i>European Journal of Operational Research</i> , 2011, 215, 679-687.	5.7	46
164	Tuberculosis Among Participants in an Academic Global Health Medical Exchange Program. <i>Journal of General Internal Medicine</i> , 2011, 26, 841-845.	2.6	12
165	Bayesian methods for fitting mixture models that characterize branching tree processes: An application to development of resistant TB strains. <i>Statistics in Medicine</i> , 2011, 30, 2708-2720.	1.6	1
166	Models to understand the population-level impact of mixed strain M. tuberculosis infections. <i>Journal of Theoretical Biology</i> , 2011, 280, 88-100.	1.7	28
167	Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure. <i>Journal of the Royal Society Interface</i> , 2011, 8, 1510-1520.	3.4	16
168	Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. <i>International Journal of Epidemiology</i> , 2011, 40, 417-428.	1.9	105
169	Drug Resistance Surveillance in Resource-Poor Settings: Current Methods and Considerations for TB, HIV, and Malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 84, 192-199.	1.4	20
170	Mixed-Strain Mycobacterium tuberculosis Infections among Patients Dying in a Hospital in KwaZulu-Natal, South Africa. <i>Journal of Clinical Microbiology</i> , 2011, 49, 385-388.	3.9	71
171	Epidemiologic Inference From the Distribution of Tuberculosis Cases in Households in Lima, Peru. <i>Journal of Infectious Diseases</i> , 2011, 203, 1582-1589.	4.0	58
172	Dynamic Health Policies for Controlling the Spread of Emerging Infections: Influenza as an Example. <i>PLoS ONE</i> , 2011, 6, e24043.	2.5	23
173	Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru. <i>Emerging Infectious Diseases</i> , 2011, 17, 969-975.	4.3	23
174	Estimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study. <i>BMC Public Health</i> , 2010, 10, 355.	2.9	9
175	What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of <i>Streptococcus pneumoniae</i> ?. <i>Journal of the Royal Society Interface</i> , 2010, 7, 905-919.	3.4	83
176	The Prevalence and Drug Sensitivity of Tuberculosis among Patients Dying in Hospital in KwaZulu-Natal, South Africa: A Postmortem Study. <i>PLoS Medicine</i> , 2010, 7, e1000296.	8.4	98
177	Negative Controls. <i>Epidemiology</i> , 2010, 21, 383-388.	2.7	923
178	Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 426-432.	5.6	82
179	The Impact of Realistic Age Structure in Simple Models of Tuberculosis Transmission. <i>PLoS ONE</i> , 2010, 5, e8479.	2.5	36
180	Does Current Drug Resistance Surveillance Provide Useful Information in Tuberculosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 82-83.	5.6	0

#	ARTICLE	IF	CITATIONS
181	Latent Coinfection and the Maintenance of Strain Diversity. <i>Bulletin of Mathematical Biology</i> , 2009, 71, 247-263.	1.9	30
182	No coexistence for free: Neutral null models for multistrain pathogens. <i>Epidemics</i> , 2009, 1, 2-13.	3.0	130
183	Mathematical models of the epidemiology and control of drug-resistant TB. <i>Expert Review of Respiratory Medicine</i> , 2009, 3, 67-79.	2.5	35
184	Personal digital assistants to collect tuberculosis bacteriology data in Peru reduce delays, errors, and workload, and are acceptable to users: cluster randomized controlled trial. <i>International Journal of Infectious Diseases</i> , 2009, 13, 410-418.	3.3	29
185	Use of Cumulative Incidence of Novel Influenza A/H1N1 in Foreign Travelers to Estimate Lower Bounds on Cumulative Incidence in Mexico. <i>PLoS ONE</i> , 2009, 4, e6895.	2.5	29
186	Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. <i>Lancet</i> , 2008, 372, 1473-1483.	13.7	261
187	Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 16302-16307.	7.1	39
188	Seasonality of Antibiotic-Resistant <i>Streptococcus pneumoniae</i> That Causes Acute Otitis Media: A Clue for an Antibiotic-Restriction Policy?. <i>Journal of Infectious Diseases</i> , 2008, 197, 1094-1102.	4.0	93
189	Challenges in Estimating the Total Burden of Drug-resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1302-1306.	5.6	47
190	Are Survey-Based Estimates of the Burden of Drug Resistant TB Too Low? Insight from a Simulation Study. <i>PLoS ONE</i> , 2008, 3, e2363.	2.5	19
191	Antiviral Resistance and the Control of Pandemic Influenza. <i>PLoS Medicine</i> , 2007, 4, e15.	8.4	182
192	MATHEMATICAL MODELS OF TUBERCULOSIS: ACCOMPLISHMENTS AND FUTURE CHALLENGES. , 2007, , .		9
193	Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. <i>Journal of the Royal Society Interface</i> , 2007, 4, 523-531.	3.4	112
194	Emergent heterogeneity in declining tuberculosis epidemics. <i>Journal of Theoretical Biology</i> , 2007, 247, 765-774.	1.7	30
195	Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfecting populations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7042-7047.	7.1	107
196	Incident Tuberculosis among Recent US Immigrants and Exogenous Reinfection. <i>Emerging Infectious Diseases</i> , 2005, 11, 725-728.	4.3	49
197	Modeling epidemics of multidrug-resistant <i>M. tuberculosis</i> of heterogeneous fitness. <i>Nature Medicine</i> , 2004, 10, 1117-1121.	30.7	249
198	Isoniazid Resistance and the Future of Drug-Resistant Tuberculosis. <i>Microbial Drug Resistance</i> , 2004, 10, 280-285.	2.0	52

#	ARTICLE	IF	CITATIONS
199	Transmission Dynamics and Control of Severe Acute Respiratory Syndrome. Science, 2003, 300, 1966-1970.	12.6	1,281
200	The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infectious Diseases, The, 2003, 3, 13-21.	9.1	151